Court extends restraining order blocking generic Lotrel sales

Share this article:

Novartis said a Federal Court judge extended a temporary restraining order on sales of generic versions of its blood pressure drug Lotrel manufactured by Teva Pharmaceutical Industries.

However, the judge did continue to allow the sale of generic copies of Lotrel that had reached distributors and customers before the court’s initial temporary restraining order on May 19, the day after the FDA approved Teva’s generic version of the drug. Analysts said it is unclear how much inventory was already shipped.

 

Novartis claims Lotrel has valid patent rights until 2017 and that Teva’s generic version of the drug infringes on that patent. A final ruling in the US District Court for the District of New Jersey is expected in the “near future,” Novartis said in a statement.

Lotrel, which is only sold in the US, had 2006 sales of $1.3 billion.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...